R U OK, page-26

The reason for the delay was explained by JF years ago.

Believe it or not they decided to wait for FDA approval before launching in Europe as they thought they could achieve a higher sale price for the product on a worldwide scale. Of course the fact they wasted well over three years of patent life didn't come into consideration. The FDA non approval is another story.

With the current sales volumes in the dozens of countries selling Vivagel (which they refuse to divulge) which we all know amounts to precision little, the patents will expire before any meaningful revenue is achieved and then some company who knows what they are doing will move in and show them how to sell and market.

I have no doubt that SPL7013 has enough potential to be a company maker. To date it's a sad tale.